HomeCompareMITSF vs JNJ

MITSF vs JNJ: Dividend Comparison 2026

MITSF yields 1.70% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.6K in total portfolio value· pulled ahead in Year 8
10 years
MITSF
MITSF
● Live price
1.70%
Share price
$39.23
Annual div
$0.67
5Y div CAGR
16.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$975.13
Full MITSF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — MITSF vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMITSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MITSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MITSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MITSF
Annual income on $10K today (after 15% tax)
$144.79/yr
After 10yr DRIP, annual income (after tax)
$828.86/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, JNJ beats the other by $3,208.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MITSF + JNJ for your $10,000?

MITSF: 50%JNJ: 50%
100% JNJ50/50100% MITSF
Portfolio after 10yr
$28.2K
Annual income
$2,862.51/yr
Blended yield
10.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MITSF
No analyst data
Altman Z
2.3
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MITSF buys
0
JNJ buys
0
No recent congressional trades found for MITSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMITSFJNJ
Forward yield1.70%2.14%
Annual dividend / share$0.67$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.3%28%
Portfolio after 10y$25.9K$30.5K
Annual income after 10y$975.13$4,749.88
Total dividends collected$4.9K$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MITSF vs JNJ ($10,000, DRIP)

YearMITSF PortfolioMITSF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,898$198.10$10,594$274.49+$304.00MITSF
2$11,896$234.66$11,294$360.69+$602.00MITSF
3$13,007$278.40$12,133$476.91+$874.00MITSF
4$14,248$330.86$13,156$635.42+$1.1KMITSF
5$15,639$393.94$14,432$854.61+$1.2KMITSF
6$17,204$469.99$16,056$1,162.76+$1.1KMITSF
7$18,970$561.96$18,175$1,604.53+$795.00MITSF
8← crossover$20,972$673.51$21,009$2,252.68$37.00JNJ
9$23,249$809.28$24,911$3,229.73$1.7KJNJ
10$25,852$975.13$30,458$4,749.88$4.6KJNJ

MITSF vs JNJ: Complete Analysis 2026

MITSFStock

Mitsui & Co., Ltd. operates as a general trading company worldwide. The company engages in the manufacture, export, and import of iron and steel products; automotive components; operation of steel processing service centers; trading of automotive, electrical, special, and stainless steel; manufacture, repair, and fabrication of wind turbine towers and flanges; gas distribution businesses; and coal mining, power generation, ferrous alloy, infrastructure maintenance, and water pumping activities. It also explores, develops, and produces oil, natural gas, and LNG; trades in petroleum products, crude oil, coal, uranium, and LNG; offers FPSO/FSO, fright car, truck, and locomotive leasing services; sells electric power facilities; and develops railway and transportation infrastructures. The company engages in logistics businesses; wholesale, retail, rental, and finance of construction and mining equipment; multimodal transportation, warehousing, and rolling stock leasing; sale, purchase, and leasing of aircraft and aero engines; leasing and financing activities; and development, process, and marketing of underground resources, and recycling of surface resources. It also provides electric-arc-furnace, construction materials processing, construction flat-rolled steel, shapes, bars, wire rods, and steel structure materials; methanol, ammonia, chlor-alkali, industrial, gas, and basic chemicals; salt; performance, advanced, specialty, and living, and environmental materials; agrochemicals and fertilizers, and animal and human nutrition products; refined sugar, oils and fats, proteins, grains, and food and beverage products; contract food services; and healthcare products. The company offers mobile communications; commodity derivative trading; venture investment and asset management services; real estate development, management, leasing, and brokerage services; and ship charter operation services. Mitsui & Co., Ltd. was incorporated in 1947 and is headquartered in Tokyo, Japan.

Full MITSF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MITSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MITSF vs SCHDMITSF vs JEPIMITSF vs OMITSF vs KOMITSF vs MAINMITSF vs ABBVMITSF vs MRKMITSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.